Live feed08:05:00·11dPRReleasevia QuantisnowEmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityByQuantisnow·Wall Street's wire, on your screen.LTRN· Lantern Pharma Inc.Health Care
